Volume | 205,892 |
|
|||||
News | - | ||||||
Day High | 3.55 | Low High |
|||||
Day Low | 3.2375 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Galectin Therapeutics Inc | GALT | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
3.25 | 3.2375 | 3.55 | 3.50 | 3.29 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
2,347 | 205,892 | $ 3.39 | $ 696,981 | - | 1.28 - 4.2684 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
17:18:05 | 1 | $ 3.55 | USD |
Galectin Therapeutics Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
215.23M | 61.85M | - | 0 | -44.81M | -0.72 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Galectin Therapeutics News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical GALT Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 3.37 | 3.55 | 2.88 | 3.27 | 211,193 | 0.188 | 5.58% |
1 Month | 2.38 | 4.2684 | 2.26 | 3.55 | 314,143 | 1.18 | 49.50% |
3 Months | 1.71 | 4.2684 | 1.59 | 3.03 | 156,712 | 1.85 | 108.07% |
6 Months | 2.07 | 4.2684 | 1.555 | 2.65 | 106,249 | 1.49 | 71.88% |
1 Year | 1.85 | 4.2684 | 1.28 | 2.31 | 80,945 | 1.71 | 92.32% |
3 Years | 4.00 | 5.70 | 1.02 | 3.23 | 331,984 | -0.442 | -11.05% |
5 Years | 4.76 | 5.70 | 1.02 | 3.03 | 399,582 | -1.20 | -25.25% |
Galectin Therapeutics Description
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its lead galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis. |